Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients. For the neurologist working in an everyday physician’s office, a key question arises: How to distinguish the few who experience a meaningful clinical benefit, from the many who do not? This question has not yet been adequately addressed in the available literature.
LimmrothVPutzkiNGoodmanA. Data From Prolonged-Release Fampridine Trials Confirm that 20% Improvement in Walking Speed is Clinically Meaningful. http://www.posters2view.com/ECTRIMS2011/view.php?nu=476 (2011; accessed 1 March 2013_).
7.
JefferyDRPharrEP. Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evid2010; 5: 107–112.
8.
KaufmanMMoyerDNortonJThe significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler2000; 6: 286–290.
9.
HobartJBlightARGoodmanA. Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology, 2013: 80: 1509–1517.
10.
Red Book. 114th ed. City: Thomson Reuters Healthcare, 2010, pp. 216: New York, USA.
